Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 3/20 | 0.75 |
| ▸ | TDP2 | O95551 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | CDC25B | P30305 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | GALK1 | P51570 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bilawsone SCHEMBL30884954 | 1.00 | APAF1 (0.75) | APAF1TDP2MEN1KMT2ACDC25B | |
| SCHEMBL16745426 | 0.87 | APAF1 (0.58) | APAF1TDP2MEN1KMT2ACDC25B | |
| SCHEMBL15198853 | 0.87 | APAF1 (0.58) | APAF1TDP2MEN1KMT2ACDC25B | |
| SCHEMBL10068409 | 0.86 | P2RX7 (0.74) | APAF1TDP2MEN1KMT2ACDC25B | |
| SCHEMBL29678361 | 0.86 | APAF1 (1.00) | APAF1TDP2MEN1KMT2ACDC25B | |
| SCHEMBL461648 | 0.86 | APAF1 (1.00) | APAF1TDP2MEN1KMT2ACDC25B | |
| SCHEMBL20100968 | 0.84 | MAPT (0.62) | APAF1TDP2MEN1KMT2ACDC25B | |
| SCHEMBL20561010 | 0.83 | APAF1 (0.58) | APAF1TDP2MEN1KMT2ACDC25B | |
| SCHEMBL12280399 | 0.83 | P2RX7 (0.69) | APAF1TDP2MEN1KMT2AP2RX7 | |
| SCHEMBL29630331 | 0.82 | P2RX7 (0.76) | APAF1TDP2MEN1KMT2ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846628-B2 | Hole blocking layer containing photoconductors | XEROX CORPORATION (US) | 2010-12-07 | — | — | US | claimed |
| US-20080311497-A1 | HOLE BLOCKING LAYER CONTAINING PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2008-12-18 | — | — | US | claimed |
| US-7462433-B2 | Undercoat layer containing charge transfer molecule, andTiO2; imaging layer; charge transfer molecule complexes with the TiO2 to form coordination bonds and the coordination bonds provide a reduction in ghosting; electrophotographic imaging members; improved image quality | XEROX CORPORATION (US) | 2008-12-09 | — | — | US | claimed |
| US-20070048639-A1 | Undercoat layer containing charge transfer molecule, andTiO2; imaging layer; charge transfer molecule complexes with the TiO2 to form coordination bonds and the coordination bonds provide a reduction in ghosting; electrophotographic imaging members; improved image quality | XEROX CORPORATION (US) | 2007-03-01 | — | — | US | claimed |
| EP-2968219-B1 | NOVEL THERAPY FOR PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10245240-B2 | Treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180116977-A1 | NOVEL TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-9877932-B2 | Treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9877932-B2 | Treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170258744-A1 | NOVEL TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170258744-A1 | NOVEL TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-9655868-B2 | Treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20080268359-A1 | Single layered photoconductors | XEROX CORPORATION | 2008-10-30 | — | — | US | disclosed |
| US-20080268358-A1 | Single layered photoconductors | XEROX CORPORATION | 2008-10-30 | — | — | US | disclosed |
| US-20080268358-A1 | Single layered photoconductors | XEROX CORPORATION | 2008-10-30 | — | — | US | disclosed |
| US-20080268359-A1 | Single layered photoconductors | XEROX CORPORATION | 2008-10-30 | — | — | US | disclosed |
| US-20070048639-A1 | Undercoat layer containing charge transfer molecule, andTiO2; imaging layer; charge transfer molecule complexes with the TiO2 to form coordination bonds and the coordination bonds provide a reduction in ghosting; electrophotographic imaging members; improved image quality | XEROX CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070048639-A1 | Undercoat layer containing charge transfer molecule, andTiO2; imaging layer; charge transfer molecule complexes with the TiO2 to form coordination bonds and the coordination bonds provide a reduction in ghosting; electrophotographic imaging members; improved image quality | XEROX CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070048639-A1 | Undercoat layer containing charge transfer molecule, andTiO2; imaging layer; charge transfer molecule complexes with the TiO2 to form coordination bonds and the coordination bonds provide a reduction in ghosting; electrophotographic imaging members; improved image quality | XEROX CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2006107827-A1 | SKIN BONDING PROCESS | CREIGHTON UNIVERSITY (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10245240-B2 | Treatment of prostate carcinoma | KLK3, ACP3, PLK1 | APAF1 2521/4885TDP2 3637/4885MEN1 299/4885 |
| US-20170258744-A1 | NOVEL TREATMENT OF PROSTATE CARCINOMA | KLK3, AR, PLK1 | APAF1 2339/4885TDP2 3826/4885MEN1 404/4885 |
| US-20180116977-A1 | NOVEL TREATMENT OF PROSTATE CARCINOMA | KLK3, AR, PLK1 | APAF1 2339/4885TDP2 3826/4885MEN1 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.